Disease Landscape and Forecast Insights

Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously…

Market Outlook: Angiogenesis inhibitors continue to be the mainstay of first-line and second-line advanced or metastatic renal cell carcinoma. While PD-1 inhibitor, Opdivo entry in the second-…

The renal cell carcinoma drug market in Europe is increasingly competitive. Angiogenesis inhibitors (such as Pfizer’s Sutent and Novartis’s Votrient) and mTOR inhibitors (Pfizer’s Torisel and…

The increase in oral oncolytics has fueled an increase in oncologist dispensing of drugs either from the physician office or from a pharmacy owned by the practice or hospital, as allowed by state…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…

Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…

Angiogenesis inhibitors are the mainstay of the treatment of advanced renal cell carcinoma. However, the treatment algorithm is rapidly evolving driven by the approval of novel agents, including…

Consolidation within the oncology provider community, including hospital acquisitions of oncology practices and oncology practices joining together, is changing the dynamics in the relationship…

The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…

The treatment landscape for advanced/metastatic renal cell carcinoma includes well-established angiogenesis and mTOR inhibitors, many of which have broad labels allowing their use across several…

Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival…

A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to…